Report cover image

Chronic Pulmonary Hypertension Treatment Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Publisher Credence Research Inc
Published Feb 11, 2025
Length 200 Pages
SKU # CRRE19992958

Description

Market Overview
The global Chronic Pulmonary Hypertension Treatment Market is forecasted to increase from USD 7,025 million in 2024 to USD 10,379.12 million by 2032, representing a compound annual growth rate (CAGR) of 5% during the forecast period of 2024–2032.

Market growth is primarily driven by the increasing prevalence of chronic pulmonary hypertension, attributable to shifting lifestyle habits, an aging global population, and the rising incidence of comorbid cardiovascular and respiratory conditions. Significant advancements in drug development—including endothelin receptor antagonists, prostacyclin analogs, and phosphodiesterase-5 inhibitors—have expanded the therapeutic landscape. Furthermore, the emergence of personalized medicine and gene therapies is accelerating innovation in treatment strategies. A notable study published in the New England Journal of Medicine demonstrated that gene therapy reduced pulmonary vascular resistance by 30% in patients with hereditary pulmonary arterial hypertension. In addition, awareness campaigns and early diagnosis initiatives led by governmental and non-profit entities are playing a crucial role in market expansion.

Market Drivers

Therapeutic Innovation
Breakthrough developments in treatment have significantly advanced clinical outcomes for patients. For instance, the STELLAR trial reported that sotatercept (Winrevair) improved the 6-minute walk distance by 34.4 meters versus 1.0 meter for the placebo group after 24 weeks. Similarly, the Phase 3 A DUE trial for Opsynvi demonstrated a superior reduction in pulmonary vascular resistance, outperforming monotherapies of macitentan and tadalafil. Specifically, Opsynvi achieved a 29% reduction, compared to 12% for macitentan alone, underscoring the promise of combination therapies in enhancing therapeutic efficacy and patient well-being.

Market Challenges Analysis

Cost and Accessibility Barriers
The high cost of chronic pulmonary hypertension therapies presents a notable challenge, limiting accessibility—especially among uninsured or underinsured populations. The pricing of medications, diagnostics, and procedures is compounded by rigorous regulatory requirements from agencies such as the FDA and CDC. The financial burden associated with drug development is considerable, with average costs exceeding USD 1 billion—clinical trials alone accounting for up to 70% of this figure. These economic constraints can delay patient access to cutting-edge treatments and limit innovation among smaller pharmaceutical firms.

Segmentations

By Drug Type:

Endothelin Receptor Antagonists

PDE-5 Inhibitors

Prostacyclin Analogs

Soluble Guanylate Cyclase (SGC) Stimulators

By Route of Administration:

Oral

Intravenous/Subcutaneous

Inhalational

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America:

United States

Canada

Mexico

Europe:

United Kingdom

France

Germany

Italy

Spain

Russia

Belgium

Netherlands

Austria

Sweden

Poland

Denmark

Switzerland

Rest of Europe

Asia Pacific:

China

Japan

South Korea

India

Australia

Thailand

Indonesia

Vietnam

Malaysia

Philippines

Taiwan

Rest of Asia Pacific

Latin America:

Brazil

Argentina

Peru

Chile

Colombia

Rest of Latin America

Middle East:

United Arab Emirates

Saudi Arabia

Israel

Turkey

Iran

Rest of Middle East

Africa:

Egypt

Nigeria

Algeria

Morocco

Rest of Africa

Key Player Analysis

Johnson & Johnson (Actelion Pharmaceuticals)

Bayer AG

United Therapeutics Corporation

GlaxoSmithKline plc

Pfizer Inc.

Eli Lilly and Company

Gilead Sciences, Inc.

Arena Pharmaceuticals

Acceleron Pharma

Novartis International AG

Table of Contents

200 Pages
CHAPTER NO. 1 : INTRODUCTION
1.1.1. Report Description
Purpose of the Report
USP & Key Offerings
1.1.2. Key Benefits for Stakeholders
1.1.3. Target Audience
1.1.4. Report Scope
CHAPTER NO. 2 : EXECUTIVE SUMMARY
2.1. Chronic Pulmonary Hypertension Treatment Market Snapshot
2.1.1. Chronic Pulmonary Hypertension Treatment Market, 2018 - 2032 (USD Million)
CHAPTER NO. 3 : Chronic Pulmonary Hypertension Treatment Market – INDUSTRY ANALYSIS
3.1. Introduction
3.2. Market Drivers
3.3. Market Restraints
3.4. Market Opportunities
3.5. Porter’s Five Forces Analysis
CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE
4.1. Company Market Share Analysis – 2023
4.2. Chronic Pulmonary Hypertension Treatment Market Company Revenue Market Share, 2023
4.3. Company Assessment Metrics, 2023
4.4. Start-ups /SMEs Assessment Metrics, 2023
4.5. Strategic Developments
4.6. Key Players Product Matrix
CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS
CHAPTER NO. 6 : Chronic Pulmonary Hypertension Treatment Market – BY By Drug Type: ANALYSIS
CHAPTER NO. 7 : Chronic Pulmonary Hypertension Treatment Market – BY By Route of Administration: ANALYSIS
CHAPTER NO. 8 : Chronic Pulmonary Hypertension Treatment Market – BY By Distribution Channel: ANALYSIS
CHAPTER NO. 9 : Chronic Pulmonary Hypertension Treatment Market – BY By Region: ANALYSIS
CHAPTER NO. 10 : COMPANY PROFILES
10.1. Johnson & Johnson (Actelion Pharmaceuticals)
 10.1.1. Company Overview
 10.1.2. Product Portfolio
 10.1.3. Swot Analysis
 10.1.4. Business Strategy
 10.1.5. Financial Overview
10.2. Bayer AG
10.3. United Therapeutics Corporation
10.4. GlaxoSmithKline plc
10.5. Pfizer Inc.
10.6. Eli Lilly and Company
10.7. Gilead Sciences, Inc.
10.8. Arena Pharmaceuticals
10.9. Acceleron Pharma
10.10. Novartis International AG

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us